Advice
Following a full submission
Cinacalcet (Mimpara) is not recommended for use within NHS Scotland for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.
Addition of cinacalcet to standard treatment with phosphate binders and/or vitamin D sterols reduced serum concentrations of parathyroid hormone and was associated with a reduced risk of fractures compared to standard treatment. However the economic case was not demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- cinacalcet (Mimpara)
- SMC ID:
- 169/05
- Indication:
- Secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 09 May 2005
Additional notes
Advice 169/05 has been superseded by NICE MTA. http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/mta_resources/appraisal_117.aspx